Novartis Pays $35M To Settle Elidel Marketing False Claims Lawsuit
Mealey's (October 11, 2016, 1:14 PM EDT) -- PHILADELPHIA — Novartis Pharmaceuticals Corp. will pay $35 million to resolve a whistle-blower’s claim that the drug maker marketed Elidel for use with children under 2 and as a first-line drug, according to a settlement disclosed in Pennsylvania federal court on Oct. 5 (United States of America, ex rel. Donald R. Galmines v. Novartis Pharmaceuticals Corporation, No. 06-3213, E.D. Pa.).